Novel tools to study the relaxin-3 signalling system

The project focuses on the development of brain-penetrating small molecule ligands specifically targeting the relaxin-3 signaling system – an emerging G protein-coupled receptor (GPCR) pathway explored as a therapeutic target for anxiety, depression and eating disorders.

By leveraging both classical medicinal chemistry and in silico drug discovery approaches, the team aims to generate pharmacologically stable and selective compounds that can cross the blood-brain barrier and modulate RXFP3 activity in vivo.

These compounds will serve as essential tools for elucidating RXFP3 neurobiology and as promising candidates for future therapeutic development.